Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Coming Soon: More Targeted Oral Asthma Therapies
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.
Presenters
Facebook Comments